Hyperkalemia complicating propranolol treatment of an infantile hemangioma.
Propranolol treatment was recently reported to be successful for the management of severe infantile hemangioma. Known adverse effects of propranolol treatment include transient bradycardia, hypotension, hypoglycemia, and bronchospasm (in patients with underlying spastic respiratory illnesses), which led to a general recommendation to gradually increase propranolol dosage and closely monitor patients' hemodynamics at the onset of therapy. To date, no serious or unexpected adverse effects that required specific intervention have been reported. In this report, we describe the case of a 17-week-old female preterm infant who presented with a large, ulcerated, cutaneous-subcutaneous hemangioma of the right lateral thoracic wall, which we treated successfully with propranolol. A few days into therapy, a potentially life-threatening adverse effect, severe hyperkalemia, was observed and required treatment with loop diuretics, fluids, and nebulized salbutamol to normalize her serum potassium levels. This therapy could be gradually tapered and finally discontinued only after several weeks of propranolol treatment. Our case report indicates that, at least during the initial phase of the propranolol treatment of infantile hemangioma, close monitoring of serum electrolytes, besides the monitoring of hemodynamics and blood glucose, is necessary.
Department of Pediatrics I, University Hospital Göttingen, Kreuzbergring 36, D-37075 Göttingen, Germany. helena.pavlakovic@med.uni-goettingen.de
Helena
H
Pavlakovic
Silke
S
Kietz
Peter
P
Lauerer
Markus
M
Zutt
Max
M
Lakomek
D058666:Adrenergic beta-2 Receptor Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000420:Albuterol / Q000627:therapeutic use; D005260:Female; D005440:Fluid Therapy; D005500:Follow-Up Studies; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D007223:Infant; D011188:Potassium / Q000097:blood*; D011433:Propranolol / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000627:therapeutic use; D035441:Thoracic Wall
D058666:Adrenergic beta-2 Receptor Agonists; D000319:Adrenergic beta-Antagonists; D049994:Sodium Potassium Chloride Symporter Inhibitors; D011433:Propranolol; D000420:Albuterol; D011188:Potassium